OpenAI has introduced GPT-Rosalind, a domain-specific AI model designed for drug discovery and life sciences, which could potentially accelerate the process. However, access to the model is limited. The technology has significant implications for the pharmaceutical industry.
Impact: The development of GPT-Rosalind could significantly impact the pharmaceutical industry by speeding up drug discovery.
Not investment advice